Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ModernaTX, Inc.
The study includes a single ascending dose (SAD) stage and a multiple ascending dose (MAD) stage. Participants enrolled in the MAD stage have the option to continue treatment in an open-label extension (OLE) period that will assess long-term safety and clinical activity of mRNA-3745.
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented GSD1a with confirmation of biallelic gene encoding glucose-6-phosphatase-α (G6PC) mutations by genetic testing.
Absence of hospitalization for hypoglycemia in the 4 weeks prior to Screening
You may not be if
Solid organ transplant
Received gene therapy for GSD1a
Presence of liver adenoma \>5 centimeters (cm) in size
Diagnosis of type 1 or type 2 diabetes mellitus
Presence of liver adenoma with growth of \>2 cm or \>5 newly diagnosed liver adenomas, in the previous 2 years
Clareo Health | A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
